The precise molecular mechanism leading to LAM is not completely understood, although it is considered to be triggered by variations within the tuberous sclerosis complex (TSC1/TSC2) genes, which influence the stimulation of the mammalian target of rapamycin (mTOR) signal transduction pathway [42,43]. Here, MTOR is linked to lymphangioleiomyomatosis.